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Introduction
Cancer treatment options directed at specific molecular
targets, such as HER2/neu in breast cancer and c-kit in
chronic myeloid leukemia and gastrointestinal stromal sar-
comas, have proven effective [1–4]. HER2/neu is amplified
in about 20–30% of human breast cancers and is a
valuable biologic marker [5]. There is substantial evidence
that overexpression of HER2/neu is associated with
multiple adverse prognostic factors and aggressive clinical
behavior, including early metastatic disease and un-
responsiveness to current treatment modalities [6–8].
Immunotherapy could offer potential therapeutic benefit to
patients with HER2/neu+ tumors by impairing the
downstream molecular signaling pathways, leading to
CTL = cytotoxic T lymphocytes; DOX = doxorubicin; FITC = fluorescein isothiocyanate; HA = hemagglutinin; IFN = interferon; IL = interleukin; PTX =
paclitaxel; Th = T helper (Th) cells; VRP = Venezuelan equine encephalitis virus replicon particles.
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Abstract
Introduction: The purpose of the present study was to
determine whether cytotoxic chemotherapeutic agents
administered prior to immunotherapy with gene vaccines could
augment the efficacy of the vaccines.
Methods: Mice were injected in the mammary fat pad with an
aggressive breast tumor cell line that expresses HER2/neu.
The mice were treated 3 days later with a noncurative dose of
either doxorubicin or paclitaxel, and the following day with a
gene vaccine to HER2/neu. Two more doses of vaccine were
given 14 days apart. Two types of gene vaccines were tested:
a plasmid vaccine encoding a self-replicating RNA (replicon) of
Sindbis virus (SINCP), in which the viral structural proteins
were replaced by the gene for neu; and a viral replicon particle
derived from an attenuated strain of Venezuelan equine
encephalitis virus, containing a replicon RNA in which the
Venezuelan equine encephalitis virus structural proteins were
replaced by the gene for neu.
Results: Neither vaccination alone nor chemotherapy alone
significantly reduced the growth of the mammary carcinoma. In
contrast, chemotherapy followed by vaccination reduced tumor
growth by a small, but significant amount. Antigen-specific
CD8+ T lymphocytes were induced by the combined treatment,
indicating that the control of tumor growth was most probably
due to an immunological mechanism. The results demonstrated
that doxorubicin and paclitaxel, commonly used chemo-
therapeutic agents for the treatment of breast cancer, when
used at immunomodulating doses augmented the antitumor
efficacy of gene vaccines directed against HER2/neu.
Conclusions: The combination of chemotherapeutic agents
plus vaccine immunotherapy may induce a tumor-specific
immune response that could be beneficial for the adjuvant
treatment of patients with minimal residual disease. The
regimen warrants further evaluation in a clinical setting.
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tumor proliferation and resistance to established cytotoxic
agents [9]. In breast cancer patients, traztuzumab has
produced remarkable results, providing substantial support
for an immunotherapeutic approach to cancer [10].
Vaccination as a form of specific immunotherapy for
cancer has been considered for many years [11,12].
Tumors that express specific antigens, such as melanoma
and breast cancer, are considered suitable candidates for
vaccine therapy [13,14]. Peptide antigens resulting from
amplified gene transcription and translation are expressed
on the cell surface in the context of class I histo-
compatibility antigens and constitute a well-defined target
for cytotoxic T-cell-mediated destruction [15,16]. Encou-
raging  in vitro and animal studies have led to several
clinical trials of vaccine therapy for malignant disorders
[13,17,18]. Although a few phase I trials and one phase III
trial have indicated a possible benefit from vaccine therapy
in an adjuvant setting, vaccination remains an experimental
modality of cancer treatment [19].
The HER2/neu gene encodes a 185 kDa transmembrane
growth factor receptor (p185) with tyrosine kinase activity
[20]. Although normally expressed in many cells through-
out the body, p185 is greatly overexpressed on the
plasma membrane of some tumor cells. This over-
expression makes the tumor cells recognizable by the
immune system [21]. Tumors can circumvent the immune
response, however, by downregulating an overexpressed
antigen such as p185 or by secreting immune response
blocking cytokines such as transforming growth factor
beta [19]. Also, since tumor cells are derived from normal
cells, host tolerance often extends to the tumor [22].
As demonstrated by several groups [23–27], including
our own [28], DNA or gene vaccines directed against
HER2/neu protected mice from challenge with HER2/neu-
overexpressing murine mammary tumor cell lines. In
addition, treatment with a gene vaccine prolonged the
survival of neu transgenic mice, although all the mice
eventually developed fatal breast tumors [28]. Thus, although
vaccination prior to challenge with a breast tumor can
prevent tumor growth, stopping the growth of an existing
tumor remains to be accomplished in murine models.
In the search for alternatives that could increase the
efficacy of vaccine treatment, we focused our efforts on
adjunctive chemotherapy. Previous publications note that
chemotherapeutic agents administered at low doses
increased immune-mediated tumor destruction through
stimulation of cytotoxic lymphocytes and induction of
mediators that are directly or indirectly involved in cell
killing [29–32]. Other publications have contained
preclinical and clinical data demonstrating increased
tumor control with treatment modalities that combine
immunotherapy and chemotherapy [33–40]. Based on
these reports, we tested whether vaccine therapy
combined with cytotoxic chemotherapeutic agents could
augment the efficacy of either agent used alone in a
rapidly growing murine mammary tumor model.
Materials and methods
Cell lines
The previously described A2L2 cells were maintained in
monolayer culture in Eagle’s minimum essential medium
supplemented with 5% fetal calf serum, sodium pyruvate,
nonessential amino acids, L-glutamine, and vitamins
(GIBCO-BRL, Grand Island, NY, USA), incubated in a
humidified 5% CO2–95% air incubator at 37°C [28].
Mice
Female BALB/c mice (6–8 weeks of age, weighing
approximately 20 g) were purchased from the National
Cancer Institute (Frederick, MD, USA). All experiments
were performed in accordance with pre-approved
institutional protocols and with the guidelines of the
Animal Care and Use Committee of the University of Texas
MD Anderson Cancer Center.
Tumor injection and chemotherapeutic agents
The cytotoxic effects of doxorubicin (DOX) and paclitaxel
(PTX) on A2L2 cells were determined by in vitro growth
inhibition assays. For in vitro tests, DOX and PTX were
purchased in crystalline form (Sigma Chemicals, St Louis,
MO, USA). One-use aliquots of PTX (0.01 M in dimethyl-
sulfoxide) were stored at –20°C, and one-use aliquots of
DOX (2 mg/ml in sterile normal saline) were stored at 4°C.
For in vivo experiments, DOX (Gencia, Irvine, CA, USA)
and PTX (Taxol®; Bristol-Myers Squibb, Princeton, NJ,
USA) were diluted in 0.9% sterile sodium chloride solution
before injection. To determine the in vivo efficacy and the
optimal dose of each agent that would result in an
approximately 50% reduction in tumor growth, preparatory
dose-finding experiments were performed. Both chemo-
therapeutic drugs were administered 3 days after a tumor
challenge of 2.5 × 104 A2L2 cells injected into the
mammary fat pad.
Mice were anesthetized by inhalation of isoflurane using a
special apparatus developed by the veterinarians at the
University of Texas MD Anderson Cancer Center. A 0.5 cm
incision was made above the top-most breast to reveal the
underlying fat pad. A suspension of 2.5 × 104 A2L2 cells
were injected in 0.1 ml normal saline. The incision was
closed with a wound clip. These wound clips were
removed after 7 days (if they had not fallen off already).
Tumor dimensions were measured in perpendicular
directions three times a week with microcalipers, and the
tumor mass was calculated using the following formula:
tumor mass = (a × b2) / 2, where a is the largest diameter
and b is the shortest dimension perpendicular to a.R277
DOX was given intravenously via the tail vein at doses
ranging from 2.5 to 10.0 mg/kg, and PTX was given
intraperitoneally at dose levels ranging from 10.0 to
30.0 mg/kg. The dose causing a 50% reduction in tumor
growth was determined as 5.0 mg/kg for DOX and as
25.0 mg/kg for PTX based upon effectiveness.
To eliminate the possibility that the A2L2 cell line was
resistant to DOX and PTX, we performed an in vitro
viability assay. Both DOX and PTX killed A2L2 cells in a
dose-dependent manner (data not shown).
Plasmid vaccine
The SINCP-βgal plasmid was obtained from Chiron
Corp. (Emeryville, CA, USA) and has been described in
detail elsewhere [41,42]. The vaccine is designed to
generate a self-replicating vector RNA (replicon) based
on Sindbis virus [42] and was prepared as follows. The
rat neu sequence was excised from the plasmid pSV2-
neu (obtained from Dr M-C Hung, University of Texas
MD Anderson Cancer Center) and was inserted into
SINCP following excision of the gene for β-gal. This
plasmid was designated SINCP-neu. Mice were
vaccinated in the quadriceps muscle by injections
containing 100 µg SINCP-neu in 100 µl of 0.25%
bupivacaine (Sigma Chemicals) in normal saline using a
26-gauge needle.
Venezuelan equine encephalitis virus replicon particles
vaccine
Venezuelan equine encephalitis virus replicon particles
(VRP) encoding the same rat neu gene were prepared by
AlphaVax (Research Triangle Park, NC, USA). VRP
vaccines are virus replicon particles comprised of the
Venezuelan equine encephalitis virus structural proteins
containing a replicon RNA expressing heterologous
genes. The preparation of VRP has been described in
detail previously [43]. VRP-neu or a control vaccine
encoding the hemagglutinin (HA) gene of the influenza
virus, VRP-HA, were injected into the foot pad of mice in a
volume of 10 µl containing 106 infectious units using a
25 µl Hamilton syringe with an attached 26-gauge needle
(Hamilton Co., Reno, NV, USA).
Experimental tumor model and treatment
The ‘race model’ is an experimental design for
investigating the efficacy of sequentially administered
chemotherapy followed by the vaccine in a large tumor
burden setting. In this model, cytotoxic drugs are
administered on the third day following tumor cell injection
and the vaccine is administered 1 day later. All immuniza-
tions were started on the fourth day after tumor cell
injection and were repeated on days 18 and 32. A
different foot was injected each time. Appropriate
controls, including normal saline for DOX and 10%
cremaphor/10% ethanol (Sigma Chemicals) for PTX, were
included in all experiments. Mice with tumors weighing 1 g
received euthanasia in a CO2 chamber.
In vitro growth inhibition assay
A2L2 cells were suspended in culture medium at a density
of 3 × 104 cells/ml. Then 1.5 × 103 cells in 50 µl were
plated into 96-well flat-bottom plates. Following incubation
for 24 hours at 37°C, drugs, vehicles and controls
consisting only of medium and cells were dispensed in
50 µl volumes in duplicate into the appropriate wells. DOX
was tested at concentrations ranging from 0.0625 to
125 µg/ml, and PTX was tested at concentrations ranging
from 0.1875 to 375 µg/ml.
Cell viability was assessed by the MTS-CellTiter 96®
aqueous non-radioactive cell proliferation assay (Promega,
Madison, WI, USA) according to the manufacturer’s
protocol at 24 and 48 hours of culture. Because the
tetrazolium compound of MTS-CellTiter 96® is bioreduced
into a formazan, its metabolism could be assayed by
optical density at 490 nm using a photometric plate
reader.
In vitro cell cultures
Spleens from treated mice were removed aseptically and
homogenized gently between two frosted slides. The
splenocytes were cultured in RPMI 1640 supplemented
with 10% fetal bovine serum (HyClone, Logan, UT, USA),
1% nonessential amino acids, 100 mM sodium pyruvate,
2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml strepto-
mycin, and 50 µM 2-mercaptoethanol (GIBCO-BRL).
Splenocyte cultures were incubated with a specific
peptide (described next) for 5 days in a humidified 5%
CO2–95% air incubator at 37°C before cytokine analysis.
Synthetic peptide
The rat HER2/neu-derived peptide HER2p780 (amino
acids 780–788; PYVSRLLGI) was obtained from M
Campbell (Peptide Synthesis Facility, University of Texas
MD Anderson Cancer Center). This peptide was
previously shown to induce specific immunity against
HER2/neu [44]. HER2p780 in crystalline form was
dissolved in complete culture medium and mixed with the
splenocyte cultures at a concentration of 70 µg/ml.
Measurement of intracellular IFN-γ γ levels
To enhance intracellular cytokine levels, peptide-
stimulated splenocytes were resuspended at a density of
(1–2) × 106 cells/ml, and cells were reactivated by 6-hour
incubation at 37°C in the presence of 10 ng/ml phorbol
12-myristate 13-acetate (Sigma Chemicals), 250 ng/ml
calcium ionophore (Sigma Chemicals) and 1 µl/ml
brefeldin A (GolgiPlu™; BD Pharmingen Biosciences, San
Diego, CA, USA). The cells were then treated with Fc
block (BD Pharmingen Biosciences) for 15 min to reduce
nonspecific binding.
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anti-IFN-γ, with peridinin chlorophyll protein-conjugated
anti-CD3 and with phycoerythrin-conjugated anti-CD8
monoclonal antibodies (BD Pharmingen Biosciences)
were performed according to the manufacturer’s protocol.
A positive control using commercially obtained MIC-1
cells (BD Pharmingen Biosciences) and negative controls
with nonstimulated splenocytes were also included.
To rule out nonspecific background staining, we used
isotype controls (BD Pharmingen Biosciences) for each
monoclonal antibody. Samples were analyzed by three-color
flow cytometry analysis using a FACS Calibur (BD, Franklin
Lakes, NJ, USA), and data were analyzed using WinMDI 2.8
software (freely downlaodable from http://facs.scripps.edu)).
Statistical analysis
All statistical analyses were performed by two-way
analysis of variance using Prism 4.0 software (Graphpad
Software, San Diego, CA, USA). The error bars in Figures
1–3 represent the standard error of the mean. Statistical
analysis, power analysis and the sample size per group
were evaluated and found to be statistically acceptable by
Lyle Broemling, PhD, Associated Professor of Biostatistics,
University of Texas MD Anderson Cancer Center.
Results
The antitumor effect of DOX followed by vaccination
with SINCP-neu
Using the race model, we investigated the efficacy of
chemotherapy followed by vaccination to inhibit tumor
growth. The cytotoxic agent DOX was administered
3 days after inoculation of 2.5 × 104 A2L2 cells in the
mammary fat pad. Either the SINCP-neu plasmid gene
vaccine or the control plasmid SINCP-βgal was
administered 1 day later and administered again on days
18 and 32.
Tumor growth over a period of 42 days is shown in Fig. 1.
The group of 10 mice treated with DOX and SINCP-neu
had a significant delay in tumor progression compared
with the mice treated with DOX and SINCP-βgal
(P < 0.0001). The mean tumor mass for the SINCP-βgal
plasmid control group on day 40 was 1062.8 ± 44.8 mg,
compared with 888.5 ± 51.7 mg for the SINCP-neu
group. Control groups of 10 mice receiving treatment with
only DOX, SINCP-βgal, SINCP-neu or normal saline had
nearly identical tumor growth to that in the group given
DOX followed by SINCP-βgal; the mean tumor mass for
these four control groups was greater than 1 g by day 42.
The day 42 mean value for DOX alone (open square) and
the day 36 mean value for normal saline (inverted triangle)
are shown in Fig. 1. The only significant difference in any
of the control groups was for the mice treated with only
normal saline; these mice were sacrificed on day 36
because they were moribund.
Absence of an antitumor effect of PTX followed by
vaccination with SINCP-neu
Again using the race model, we investigated the efficacy
of PTX followed by vaccination to inhibit tumor growth.
PTX was administered 3 days after inoculation of 2.5 × 104
A2L2 cells in the mammary fat pad, and either SINCP-neu
or SINCP-βgal was administered 1 day later and admini-
stered again on days 18 and 32. Tumor growth was
monitored for a total of 35 days. Unlike the results for
DOX (Fig. 1), PTX treatment followed by vaccination did
not significantly reduce tumor growth. PTX alone did not
reduce tumor growth compared with the vehicle of 10%
cremaphor/10% ethanol used to dissolve the PTX, and
there was no reduction in tumor growth by either SINCP-
neu or SINCP-βgal used alone (data not shown).
Antitumor effect of VRP-neu with DOX or PTX
In our next experiment, we again used the race model to
evaluate the combined effect of either DOX or PTX
followed by vaccination. As shown in Fig. 2, tumor progres-
sion was significantly delayed in mice treated with DOX
followed by VRP-neu compared with mice treated with
DOX followed by VRP-HA (P < 0.0001). The mean tumor
mass on day 35 for mice treated with DOX and VRP-neu
was 416.3 ± 47.6 mg, compared with 720.6 ± 133.8 mg
for mice treated with DOX and VRP-HA. The mean for the
DOX and VRP-neu group was also significantly less than
that for mice treated with DOX alone (Fig. 2, open square)
or with normal saline (Fig. 2, inverted triangle).
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Figure 1
Tumor growth in groups of 10 mice treated with doxorubicin (DOX)
followed by the plasmid gene vaccine SINCP-neu (lower line)
containing the gene for neu, compared with DOX followed by the
negative control plasmid vaccine SINCP-βgal lacking the gene for neu
(upper line). The mean tumor volume for mice treated with only DOX
() is shown for day 42, and the mean tumor volume for mice treated
with only normal saline () is shown for day 36.When PTX was substituted for DOX in the race model,
tumor growth was again significantly delayed for
vaccination with VRP-neu compared with vaccination with
VRP-HA (Fig. 3). In this experiment the mean tumor mass
on day 35 for mice treated with PTX and VRP-neu was
525.4 ± 44.4 mg, compared with 723.6 ± 108.5 mg for
mice treated with PTX and VRP-HA. The mean tumor
mass for the PTX and VRP-neu group on day 35 was also
significantly lower than for groups of control mice treated
with only PTX (Fig. 3, open square) or with only the vehicle
control (Fig. 3, inverted triangle).
Induction of antigen-specific CD8+/IFN-γ γ+ T lymphocytes
Cytotoxic T lymphocytes (CTL) form a distinct CD8+ T-cell
population that is capable of killing antigen-bearing target
cells after interacting with the T-cell antigen receptor [45].
The generation of such protective immunity against foreign
antigens is coordinated to a large extent by cytokines
produced by certain T-cell subsets. IFN-γ is a relevant
mediator in the activation of CTL populations by Th cells
[46]. Furthermore, in vitro studies have revealed
substantial evidence supporting a direct correlation
between IFN-γ production and CTL activity [25,47–52].
To determine the underlying mechanism of tumor growth
inhibition by our treatment groups, we compared the
number of HER2/neu-specific CD8+ cells containing intra-
cellular IFN-γ after various treatments. As shown in Fig. 4,
PYVSRLLGI-stimulated spleen cells from mice treated
with DOX and vaccinated with VRP-neu had 2.16%
CD8+IFN-γ+ cells, compared with 0.29% for mice treated
with DOX and vaccinated with VRP-HA. Similarly,
PYVSRLLGI-stimulated spleen cells from mice treated
with PTX and vaccinated with VRP-neu had 2.25%
CD8+IFN-γ+ cells, compared with 0.52% for mice treated
with PTX and vaccinated with VRP-HA.
Treatment with chemotherapy followed by vaccination with
VRP-neu clearly induced antigen-specific CD8+IFN-γ+
T lymphocytes. This same effect was not evident for mice
vaccinated with SINCP-neu, implying that VPR-neu may
be a much more powerful gene vaccine than SINCP-neu.
As presented in Table 1, treatment with PTX increased the
number of CD8+IFN-γ+ cells after PYVSRLLGI stimulation
compared with untreated mice; however, this effect was
not potentiated by vaccination with SINCP-neu compared
with vaccination with SINCP-βgal. Treatment with DOX
did not increase the baseline number of CD8+IFN-γ+ after
PYVSRLLGI stimulation as much as did treatment with
PTX. Also, vaccination with SINCP-neu compared with
vaccination with SINCP-βgal was without effect.
Discussion
In the present study we demonstrate the synergistic
enhancement of the antitumor effect of combined chemo-
therapy and vaccine immunotherapy on tumor-bearing
mice. At the doses used, the chemotherapeutic agents
DOX and PTX had a minimal effect on the growth of a pre-
existing breast tumor when used alone (data not shown).
Similarly, the vaccines SINCP-neu and VRP-neu were not
effective at controlling the growth of a pre-existing tumor
(data not shown). These findings are in agreement with
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Figure 2
Tumor growth in 10 mice treated with doxorubicin (DOX) and the viral
replicon gene vaccine Venezuelan equine encephalitis virus replicon
particles (VRP)-neu containing the gene for neu (lower line), compared
with eight mice treated with DOX and the negative control viral replicon
gene vaccine VRP-hemagglutinin (HA) lacking the gene for neu (upper
line). DOX alone () or saline alone () were also tested in groups of
eight and 10 mice, respectively, and the values are shown for day 35.
Figure 3
Tumor growth in groups of 10 mice treated with paclitaxel (PTX) and
the viral replicon gene vaccine Venezuelan equine encephalitis virus
replicon particles (VRP)-neu containing the gene for neu (lower line),
compared with mice treated PTX and the negative control viral replicon
gene vaccine VRP-hemagglutinin (HA) lacking the gene for neu (upper
line). PTX alone () or vehicle control () were also tested in groups
of 10 mice, and the values are shown for day 35.previous data showing that a number of current vaccines
developed against tumor-associated antigens have failed
to prevent growth and metastasis of established tumors in
both animal and human studies, despite documentation of
antigen-directed immune activation [12,45,53].
Various approaches to overcoming the low immuno-
genicity of vaccines or to optimize antigen presentation
have yielded promising results, and many preclinical and
clinical investigational studies are under way [22,54–57].
Nonetheless, the use of cancer vaccines is at present
limited to adjuvant therapy, preferably in the setting of
minimal residual disease.
We have previously shown that the plasmid ELVIS-neu, an
earlier version of the plasmid SINCP-neu used in this
project, induced antitumor immunity when used to
vaccinate mice prior to tumor challenge [28]. Vaccination
with ELVIS-neu also prolonged the survival of neu
transgenic mice, although all the mice eventually died
[28]. In a similar experiment using neu transgenic mice,
vaccination with VRP-neu produced a much better result:
100% of the mice survived and none had breast tumors
on postmortem examination (unpublished result). This
result clearly demonstrated that VRP-neu was much more
effective for this application than ELVIS-neu and, by
inference, that VRP-neu is also better than the slightly
modified SINCP-neu. However, as already described, both
SINCP-neu and VRP-neu when used as single agents
were ineffective in the race model. Based upon these
findings, we studied whether combining chemotherapy
and vaccine immunotherapy would be more effective in
the race model than either agent used alone.
The two chemotherapeutic agents tested in this study,
DOX and PTX, are both potent anticancer agents
established as standard adjuvant therapy for breast
cancer [58]. To eliminate the possibility that the A2L2 cell
line was resistant to DOX and PTX [59,60], we performed
an in vitro viability assay. Both DOX and PTX killed A2L2
cells in a dose-dependent manner (data not shown). We
next identified the dose of each agent that would reduce
tumor growth by approximately 50%. Many animal studies
demonstrated the effectiveness of cyclophosphamide,
melphalan and DOX administered at doses as low as
3–10% of the usual cytotoxic level [30,61,62]. The doses
of DOX (5 mg/kg) and of PTX (25 mg/kg) used in our
investigation are sufficiently low to maintain lymphocyte
effector cell activity as demonstrated by the ability of the
vaccines to induce antitumor immunity. It has been
documented previously that some chemotherapeutic
drugs administered at suboptimal doses may have an
immunomodulatory activity [37,63].
We demonstrated in the present study that DOX
administered at 5 mg/kg prior to vaccination enhanced the
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Figure 4
Flow cytometric analysis of CD8+ and intracellular IFN-γ+ lymphocytes
following treatment of mice with doxorubicin (DOX) or with paclitaxel
(PTX) and vaccination with the viral replicon gene vaccine Venezuelan
equine encephalitis virus replicon particles (VRP)-neu containing the
gene for neu or the negative control viral replicon gene vaccine VRP-
hemagglutinin (HA) lacking the gene for neu.
Table 1
Induction of cytotoxic T lymphocytes following vaccinationa
CD8+ IFN-γ+ cells/CD8+ cells (%)
Vaccination None Doxorubicin Paclitaxel
VRP-HA 0.28 0.29 0.52
VRP-neu 0.80 2.16 2.25
SINCP-βgal 0.45 0.56 1.44
SINCP-neu 0.39 0.37 1.08
a Immune spleen cells from mice treated with either doxorubicin or
paclitaxel and vaccinated with SINCP-βgal, SINCP-neu, Venezuelan
equine encephalitis virus replicon particles-hemagglutinin (VRP-HA) or
Venezuelan equine encephalitis virus replicon particles-neu (VRP-neu)
were cultured for 5 days with the peptide PYVSRLLGI. Dual-positive
cells expressing CD8 and intracellular IFN-γ were quantified by flow
cytometry as described in Materials and methods.effectiveness of both the SINCP-neu gene vaccine (Fig. 1)
and the VRP-neu gene vaccine (Fig. 2). PTX administered
at 25 mg/kg, on the other hand, increased the effective-
ness of only the VRP-neu vaccine (Fig. 3). The in vivo
antitumor efficacy of PTX followed by SINCP-neu was
attributed exclusively to the effect of PTX and not to the
effect of the vaccine. The analysis of cellular immune
responses induced by combined chemotherapy and VRP-
neu vaccine therapy was in agreement with the in vivo
data that both DOX and PTX induced a high level of
antigen-specific CD8+IFN-γ+ cells (Fig. 4 and Table 1).
Although DOX and PTX induced neu-specific CD8+ T-cell
activity when combined with VRP-neu, neither the vaccine
alone nor the chemotherapy alone generated an antigen-
specific immune response by itself. DOX has been shown
to cause monocyte–macrophage functional differentiation,
which induces an augmented phagocytic activity as well
as an increased secretion of several cytokines such as
IL-1, IL-2, or tumor necrosis factor [62]. The immune
activity of DOX has therefore been linked to improved
antigen targeting and shifting of the immune response
from a Th2 type to a Th1 type, as well as an increase in
antigen-stimulated CTL activity [30,64–66].
DOX, given 7 days after an autologous vaccine engi-
neered to secrete granulocyte-macrophage colony-
stimulating factor, was also shown by Mihich and
colleagues to enhance CD8+ CTL activity [66]. However,
this result was not confirmed in a subsequent study by the
same group [64]. Although Nigam and colleagues showed
substantial CTL activity when DOX was given
concomitantly with vaccine, they did not observe a
response when chemotherapy was administered 1 week
earlier than the vaccine, demonstrating the importance of
the schedule of administration [67]. The present data
revealed that DOX could induce an antigen-specific CD8+
T-cell response when given 1 day before the vaccine;
however, if given 1 week after the vaccine, no CD8+ T-cell
response was observed (data not shown).
Based on previous findings and data with the VRP-neu
vaccine described in the present article, it can be
postulated that the immunomodulatory effect of DOX and
PTX in priming immune cells to the antigen starts within
1 week after the administration of the drug, and it appears
to enhance the capability of the vaccine to induce antigen-
specific CD8+ T-cell activity, probably by increasing
antigen presentation to effector cells through its augmen-
tation of phagocytic activity. Supporting this hypothesis,
Orsini and colleagues demonstrated that an increase in
the number of monocytic cells occurs 5 days after DOX
administration in the spleens of mice [68].
Although we have identified one mechanism underlying
the immune-enhancing effect of cytotoxic agents, other
mechanisms may be involved. This is clearly evident in our
data demonstrating that DOX and SINCP-neu inhibited
tumor growth in vivo (Fig. 1) but failed to induce antigen-
specific CD8+ T cells (Table 1). An alternative mechanism
is thus probably responsible for the antitumor effect of
DOX administration followed by SINCP-neu, and may
explain why PTX administration followed by SINCP-neu
was totally ineffective in controlling tumor growth.
Similar to DOX, PTX has been shown to activate macro-
phages directly, thus augmenting the antitumor effector
function and inducing the secretion of relevant cytokines
such as tumor necrosis factor, IL-12, and granulocyte-
macrophage colony-stimulating factor [37]. When combined
with SINCP-neu or with SINCP-βgal, however, PTX
increased the neu-specific CD8+ T-cell response by
approximately twofold, implying that PTX is capable of
inducing a tumor-specific immune response by itself rather
than through a synergistic interaction.
Several studies have reported enhanced antitumor activity
of low-dose to moderate-dose chemotherapy combined
with autologous cell vaccines [33–35,37,38], some of
which have been modified to improve the potency of the
vaccine [37,67]. Recently, in a murine model of acute
promyelocytic leukemia, the efficacy of a DNA vaccine to
the oncogenic promyelocytic leukemia-retinoic acid
receptor alpha was significantly increased when combined
with the standard all-trans retinoic acid [39,40]. In the
present study we found enhanced inhibition of tumor
growth with VRP vaccine expressing neu combined with
either DOX or PTX, possibly mediated through generation
of an antigen-specific CTL response [48–52]. DOX also
yielded an improved antitumor efficacy when combined
with a DNA plasmid designed to generate a Sindbis virus
replicon expressing neu.
Further studies are required to determine whether the
combination of chemotherapy and vaccine therapy will
prolong the survival of mice in a ‘surgical model’ in which
the tumor is surgically removed prior to treatment.
Conclusions
The results of this study demonstrate that DOX and PTX
have potential immunomodulatory activities that can be
used to improve the antitumor efficacy of gene vaccines.
The race model utilized in these studies is a very rigorous
model employing a rapidly growing tumor. The VRP-neu
vaccine, the more effective of the two vaccines evaluated,
induced CD8+IFN-γ+ T-cell responses, demonstrating a
potential immunological mechanism for the observed
delayed tumor growth. Additional studies are required to
identify other possible biological mechanisms, as well as
the optimal dosage and schedules of other potential
combination regimens using cytotoxic agents and gene
vaccines.
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